Lucis, a Paris-based preventive well being platform that makes use of blood biomarker evaluation and AI to ship personalised, science-based well being suggestions, has raised €17.1 million ($20 million) in Sequence A funding.
The spherical was led by Singular, with participation from Basic Catalyst, Y Combinator, and angels together with buyers behind Runna, Céline Lazorthes (Resilience), and Manu Lecomte. This spherical follows Lucis’s €7.2 million ($8.5 million) Seed round raised in December 2025, bringing whole funding to €24 million ($28 million).
Maxime Berthelot, co-founder and CEO, Lucis, mentioned, “We’ve seen the devastating affect of late-stage analysis first-hand. The science is already there; what’s lacking is a system designed to behave earlier than signs seem. This is the reason we constructed Lucis. By combining biomarker knowledge and AI-driven scientific insights, we will catch what the system misses. Europe deserves a healthcare mannequin that doesn’t look ahead to folks to get sick. We’re making prevention the default, fairly than a privilege.”
Based in 2025 by Maxime Berthelot and Baptiste Debever, Lucis claims to offer people with a complete, data-driven view of their well being. The platform analyses greater than 110 blood biomarkers throughout key programs, together with metabolic well being, hormones, cardiovascular threat, irritation, and nutrient ranges.
The corporate states that these outcomes are built-in into an AI-driven well being companion app, which makes use of longitudinal knowledge and medical context to offer personalised recommendation on vitamin, dietary supplements, life-style changes, and follow-up testing.
It factors out that the suggestions are constantly refined as new knowledge turns into out there and are reviewed by physicians, serving to customers perceive what actions to take, not simply what the info exhibits.
Lucis experiences that early knowledge from its rising person base of over 10,000 point out significant well being outcomes and sustained engagement. Amongst customers who accomplished a six-month follow-up, 75% improved a minimum of three biomarkers with out medicine. It additionally famous that greater than 80% opted to retest, suggesting continued engagement with the platform and their well being knowledge.
Throughout preliminary testing, 99.9% of customers had a minimum of one biomarker outdoors the optimum vary, typically with out realizing it beforehand. This underscores how potential well being dangers can simply go unnoticed with out common monitoring, says the corporate.
Since its launch in 2025, Lucis has expanded to over 10,000 customers in France, the UK, Eire, and Portugal, and has performed a couple of million biomarker exams. Moreover, the corporate has developed a neighborhood of hundreds of members and fashioned partnerships with laboratory teams akin to Eurofins and Randox.
Immediately, Lucis has a staff of 20 throughout engineering, scientific, development, and operations, together with a medical board and an increasing community of over 10 physicians offering scientific oversight.
Jeremy Uzan, co-founder and GP at Singular, mentioned, “Europe’s preventive well being class shall be gained by platforms that unite scientific credibility with AI at scale. Lucis has moved with outstanding velocity, reaching 10,000 customers in underneath a 12 months, delivering measurable outcomes and constructing a compounding knowledge benefit that units the usual for the class. We see Lucis as a transparent class winner in Europe and are excited to companion with the staff because the product continues to evolve alongside buyer wants.”
With the recent funding, the corporate goals to help growth throughout Europe and continued improvement of its AI-driven well being companion app. It plans to develop into Spain, Germany, and Italy by the top of 2026, whereas persevering with to put money into personalisation, longitudinal monitoring, and scientific security.
